Drug intelligence / Profile preview

CDX

Development stage: Preclinical
Lead developer: Hemogenyx Pharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CDX is a bispecific antibody developed by Hemogenyx Pharmaceuticals, initially in collaboration with Eli Lilly. It is being developed for the treatment of acute myeloid leukemia (AML), other blood cancers, and for conditioning in bone marrow transplantation. Hemogenyx Pharmaceuticals has licensed intellectual property related to CDX from Eli Lilly to advance the preclinical asset towards clinical trials, including IND-enabling studies for relapsed/refractory FLT3-positive AML. Selexis is involved in developing a master cell line for its production.

Targets

CD3 (T-cell surface glycoprotein CD3)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on CDX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDX.

Explore the full profile